RALB and neoplasm: In conclusion, we have shown that RALB inhibition regulates DR5 dynamics and induces apoptotic priming, and that targeting this apoptotic vulnerability with selective DR5-agonistic antibodies may be a promising strategy to improve treatment response in KRASMT CRC tumours.